靶向β-连环蛋白治疗小鼠中由突变型β-连环蛋白与K-Ras共表达诱导的肝细胞癌
研究显示突变型K-Ras(G12D)与β-连环蛋白突变体(S33Y、S45Y)共表达可在小鼠中产生肝细胞癌,其基因表达与Met-β-连环蛋白肿瘤相似度超过90%。使用CTNNB1-LNP抑制β-连环蛋白可显著降低肿瘤负荷,但对非GS阳性肿瘤亚群无影响。结论认为c-Met下游Ras激活足以与突变β-连环蛋白协同诱导临床相关肝细胞癌,β-连环蛋白抑制对β-连环蛋白阳性、GS阳性肝细胞癌有效。
要点
- 突变K-Ras与β-连环蛋白突变体共表达可在小鼠中诱导肝细胞癌。
- CTNNB1-LNP治疗组肿瘤负荷较对照组显著降低,伴β-连环蛋白靶点下降。
- 非GS阳性肿瘤亚群未受β-连环蛋白抑制影响。
核心结论
- c-Met下游Ras激活足以与突变β-连环蛋白协同诱导临床相关肝细胞癌。
- 通过临床相关手段抑制β-连环蛋白对β-连环蛋白阳性、GS阳性肝细胞癌有效。
研究设计与样本
- 使用睡美人转座子/转座酶系统在小鼠中共表达突变K-Ras(G12D)与β-连环蛋白突变体(S33Y、S45Y)建立肝细胞癌模型。
- 采用Affymetrix微阵列比较突变K-Ras-β-连环蛋白与Met-β-连环蛋白肝细胞癌的基因表达。
- 在K-Ras-β-连环蛋白小鼠中给予载有靶向CTNNB1的Dicer底物小干扰RNA的EnCore脂质纳米颗粒(CTNNB1-LNP)、乱序序列(Scr-LNP)或磷酸盐缓冲液多周期治疗。
主要发现
- 突变K-Ras-β-连环蛋白与Met-β-连环蛋白肝细胞癌基因表达相似度超过90%。
- K-Ras-β-连环蛋白肿瘤中β-连环蛋白靶点(如谷氨酰胺合成酶、白细胞细胞衍生趋化因子2、Regucalcin、Cyclin-D1)及K-Ras效应器(包括磷酸化细胞外信号调节激酶、磷酸化蛋白激酶B、磷酸化哺乳动物雷帕霉素靶蛋白、磷酸化真核翻译起始因子4E、磷酸化4E结合蛋白1、p-S6核糖体蛋白)上调。
- 注射时加入显性负性转录因子4可阻止肝细胞癌及下游β-连环蛋白和Ras信号。
- CTNNB1-LNP组肿瘤负荷较所有对照组显著降低,伴β-连环蛋白靶点及部分K-Ras效应器大幅下降,肿瘤细胞增殖和活力降低。
- 相对少数小鼠中,非GS阳性肿瘤(占总体肿瘤负荷的小部分)未受β-连环蛋白抑制影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Recently, we have shown that coexpression of hMet and mutant-β-catenin using sleeping beauty transposon/transposase leads to hepatocellular carcinoma (HCC) in mice that corresponds to around 10% of human HCC. In the current study, we investigate whether Ras activation, which can occur downstream of Met signaling, is sufficient to cause HCC in association with mutant-β-catenin. We also tested therapeutic efficacy of targeting β-catenin in an HCC model. We show that mutant-K-Ras (G12D), which leads to Ras activation, cooperates with β-catenin mutants (S33Y, S45Y) to yield HCC in mice. Affymetrix microarray showed > 90% similarity in gene expression in mutant-K-Ras-β-catenin and Met-β-catenin HCC. K-Ras-β-catenin tumors showed up-regulation of β-catenin targets like glutamine synthetase (GS), leukocyte cell-derived chemotaxin 2, Regucalcin, and Cyclin-D1 and of K-Ras effectors, including phosphorylated extracellular signal-regulated kinase, phosphorylated protein kinase B, phosphorylated mammalian target of rapamycin, phosphorylated eukaryotic translation initiation factor 4E, phosphorylated 4E-binding protein 1, and p-S6 ribosomal protein. Inclusion of dominant-negative transcription factor 4 at the time of K-Ras-β-catenin injection prevented HCC and downstream β-catenin and Ras signaling. To address whether targeting β-catenin has any benefit postestablishment of HCC, we administered K-Ras-β-catenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate small interfering RNA targeting catenin beta 1 (CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffered saline for multiple cycles. A significant decrease in tumor burden was evident in the CTNNB1-LNP group versus all controls, which was associated with dramatic decreases in β-catenin targets and some K-Ras effectors, leading to reduced tumor cell proliferation and viability. Intriguingly, in relatively few mice, non-GS-positive tumors, which were evident as a small subset of overall tumor burden, were not affected by β-catenin suppression. CONCLUSION: Ras activation downstream of c-Met is sufficient to induce clinically relevant HCC in cooperation with mutant β-catenin. β-catenin suppression by a clinically relevant modality is effective in treatment of β-catenin-positive, GS-positive HCCs. (Hepatology 2017;65:1581-1599).
引用
- Tao J, Zhang R, Singh S, et al. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice. Hepatology. 2017. PMID: 27981621. doi:10.1002/hep.28975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。